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Abstract: Chronic rhinosinusitis, one of the most common chronic medical complaints in the 
United States, seems to be increasing in incidence and prevalence, and has a significant impact 
on quality of life. Topical forms of medical therapy represent an attractive alternative for drug 
delivery to the nasal cavity and paranasal sinuses. Topical drug delivery has the advantage of 
directly acting on the site of inflammation, producing a higher concentration at the target site 
while avoiding systemic side effects. Although considerable research has been undertaken into 
improving nasal formulations in order to enhance absorption, little attention has so far been 
directed to upgrading the delivery devices. The aim of this review is to present current knowledge 
on the novel drug-delivery devices in use in the management of chronic rhinosinusitis patients, 
and to present the current available knowledge on topical drug penetration into the sinuses 
using various delivery devices. Additionally, methods used to enhance fluid sinus deposition 
are presented and the published clinical studies on the results of nebulized antibiotics in the 
treatment of chronic rhinosinusitis patients are discussed.
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Introduction
Chronic rhinosinusitis (CRS) is one of the most common chronic medical complaints 
in the United States, affecting nearly 16% of the general population, and seems to 
be increasing in incidence and prevalence, accounting for 13 million physician visits 
annually and responsible for an estimated total cost of $US6 billion/year.1,2
The etiology of CRS is thought to be multifactorial and can include bacterial 
infection, fungal colonization, environmental or aspirin sensitivities, immune or 
genetic disorders, poor mucociliary clearance, anatomic obstruction, and idiopathic 
inflammation.2,3 Chronic inflammatory disease of the paranasal sinuses was thought 
to arise from prolonged obstruction of the ostiomeatal complex, leading to stasis of 
secretions, mucociliary dysfunction, and failure to clear bacteria from the sinuses.2–4 
Although there has been a shift to anti-inflammatory therapies in CRS, bacteria and 
fungi are still likely to be powerful mediators of inflammation.4 In the blocked sinus, 
bacteria that are normally removed from the sinuses by drainage of secretions may 
proliferate. The current model of CRS pathophysiology focuses on the interaction 
of the inflammatory mucosal disease with microbial flora and the failure of innate 
immunity.2–5
In the medical management of CRS, a combination of nasal saline irrigations, 
decongestants, nasal and systemic steroids, and courses of antibiotics are currently 
prescribed.2–5 Current systemic agents, such as oral or intravenous antimicrobials 
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or corticosteroids, have significant side effects and are not 
successful in many patients. This problem has led investiga-
tors to examine local delivery of topical therapies.6 In cases 
where conservative management has failed, endoscopic sinus 
surgery (ESS) is considered.3,4
Topical forms of medical therapy represent an attrac-
tive alternative for drug delivery to the nasal cavity and 
paranasal sinuses. Topical drug delivery has the advantage 
of directly acting on the site of inflammation, producing a 
higher concentration at the target site while avoiding systemic 
side effects.6 Moreover, a successful topical nasal treatment 
will increase the response rates of conservative management 
and will decrease the need for surgery.3,6 The general aim of 
topical therapy may also lie between potentially contending 
procedures such as mechanical irrigation and pharmaceutical 
intervention.5,6 The mechanical removal of pollutants, inflam-
matory products, mucus, antigen, and bacteria/biofilms is 
often addressed by nasal irrigation. These procedures rely on 
high-volume, positive-pressure solutions to provide shearing 
forces. However, the same approach may not be appropriate 
for drug delivery since complete sinus delivery, prolonged 
mucosal contact time with local absorption, and minimal 
depletion are often the desired properties.6
Corticosteroids and antibiotics have been successfully 
delivered through intranasal means. Various methods of topi-
cal drug delivery have been used, such as nasal drops, nasal 
sprays, nebulized droplets, and larger-volume irrigation.2,6 
Despite general acceptance and clinical use of topical nasal 
therapy, only a few studies have concentrated upon the 
intranasal drug distribution. Although considerable research 
was carried out into improving nasal formulations in order to 
enhance absorption, little attention has so far been directed to 
upgrading delivery devices. The aim of the present review is 
to present the current knowledge on the novel drug delivery 
devices in use in the management of CRS patients, and to 
present the data on topical drug penetration into the sinuses. 
Additionally, methods used to enhance fluid sinus deposition 
are presented and the published clinical studies on the results 
of nebulized antibiotics in the treatment of CRS patients are 
discussed.
Current nasosinusal topical  
drug delivery systems
Nasal irrigation with isotonic or hypertonic saline is an inex-
pensive treatment and is a widely used drug delivery method 
in CRS patients. It is suggested that nasal irrigation removes 
inflammatory cells and excess secretions from the mucosal 
surface, decreases edema, enhances mucociliary clearance, 
and could be a potential route for topical drug delivery into 
the paranasal sinuses, including during the post-ESS period.6,7 
However, it was demonstrated that access of the drug to the 
paranasal sinuses during nasal irrigation may only be pos-
sible post sinus surgery.8 Therefore, in addition to saline, 
other drugs, such as steroids and antibiotics, may be applied 
during nasal irrigation in the post-ESS period.
Another current topical treatment option is the use of 
nasal pump sprays, mainly because of their ease of use. These 
generate droplets between 50 and 100 µm in diameter, and 
amounts between 70 and 150 µL are administered per puff. 
Different drug formulations are available for use with nasal 
pump sprays, such as saline, decongestants, mucolytics, or 
steroids. However, a common feature of nasal sprays is the 
large fraction deposited in the anterior region of the nose with 
no significant aerosol access to the paranasal sinuses.9,10
The recently introduced breath-actuated bidirectional 
delivery device (OptiMist™; OptiNose AS, Oslo, Norway) 
surmounted several limitations of the current methods of 
nasal spray delivery.11 The OptiMist device has a conical, 
sealing nosepiece and a mouthpiece, includes a traditional 
spray pump and a breath-actuation mechanism, and generates 
droplets of 43 µm diameter. The device is inserted into one 
nostril and the patient blows into the mouthpiece. Blowing 
closes the soft palate and transfers the oral pressure to the 
nostril. The nosepiece automatically balances the pressure 
in the nasal and oral cavities. In these instances, air is able to 
exit through the other nostril (bidirectional flow). Exhalation 
automatically triggers particle release at the moment where 
the positive dynamic pressure expands the nasal cavities. 
Since drug delivery occurs during exhalation, small particles 
cannot enter the lungs.11 Djupesland et al11 compared nasal 
deposition patterns between a conventional nasal spray and 
the OptiMist device. The deposition models generated by 
the two devices were compared in nine healthy subjects 
subsequent to technetium 99m (Tc99m) administration.11 The 
study demonstrated significantly larger initial and cumulative 
deposition in the upper posterior sector of the nasal cavities 
housing the middle meatus and sinus ostia and significantly 
lower deposition in the anterior segment.
Standard medical nebulizers can be used for aerosol 
generation and delivery into the nasal cavity.9 For efficient 
deposition into the sinuses, the aerosol should enter into the 
posterior nasal cavity. Two main nebulizer systems have 
been developed, differing in the diameter of the droplets 
produced and the flow patterns conveyed to these particles.12 
Passive-diffusion nebulizers produce particles of a smaller 
size delivered in a constant direction; nevertheless, they have 
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a slower velocity. Vortex-propelled nebulizers produce larger 
nebulized particles and centrifuge these droplets to the outer 
edge of the vortex represented by the walls of the nasal cavity 
and the paranasal sinuses. A passive-diffusion nebulizer sys-
tem is the SinuNeb™ device (PARI Respiratory Equipment, 
Inc, Midlothian, VA). The SinuNeb device generates aero-
solized particles of 3 µm in diameter and delivers particles to 
the nasal cavity by passive diffusion through a hollow tube 
with two perforations at one end, spaced apart to match the 
nares. The nebulized liquid is then inspired transnasally. The 
ViaNase™ device (Kurve Technology Inc, Lynnwood, WA) 
is a vortex-propelled nebulizer system. The ViaNase device 
generates an active vortex of nebulized particles, contained 
within an occlusive nosepiece. The ViaNase device generates 
particles of between 9 and 11 µm in size.
A recent development in the field of nebulizers is the 
pulsating aerosol delivery device.9,10,13,14 A pulsating aerosol 
is an aerosol stream superimposed by a pulsation (sound 
wave). The German company PARI developed a commercial 
pulsating aerosol delivery device, the PARI Sinus™ Pulsat-
ing Aerosol System (PARI GmbH, Starnberg, Germany) in 
2003. The PARI Sinus device contains the Pari LC Star jet 
nebulizer with a 3-µm mass median aerodynamic diameter 
and output flow rate of 6 L/minute. A pulsation of 44 Hz is 
superimposed on the aerosol stream. Further developments 
incorporating a new vibrating membrane technology were 
recently reported, as commercialized in the eFlow® elec-
tronic nebulizer (PARI). Using this technology in the PARI 
device, the particle size distribution could be sharpened and 
the flow rate could be reduced to 3 L/minute. A pressure 
wave of 25 Hz frequency with amplitude of 20 mbar was 
superimposed on the aerosol stream.13,14
For delivery, the nebulizer is attached to one nostril and a 
flow resistor is plugged into the contralateral nostril. During 
delivery the patients are instructed to close their soft palate, 
which directs the aerosol from the delivery nostril to the 
second output nostril. Using this recommended protocol an 
aerosol pathway to the nasal airways is generated and drug 
penetration to the lung can be prevented. The output resis-
tor and closure of the soft palate ensure optimal pressure 
transduction to the sinuses.9,10,13,14
Effectiveness of drug deposition  
into the sinuses
The paranasal sinuses are air-filled cavities within the bones 
of the skull, ranging in volume between 5 and 30 mL. The 
sinus is connected to the nasal cavity through the ostium, a 
narrow channel of about 1–3 mm in diameter and 10–15 mm 
in length. Since the sinuses are poorly ventilated, hollow cavi-
ties, current in vivo and in vitro experimentation has found 
inconsistent drug penetration into the sinuses.
The fundamental principles that determine the efficiency 
of deposition of aerosolized particles in the paranasal sinuses 
were described by Hyo et al.15 Using a plastic cast model, 
Hyo et al found that optimum particle size for deposition in 
the maxillary sinus varied with size of the ostia, and they 
documented no difference in deposition efficiency when 
comparing a plastic mold model and healthy volunteers.15 
Mathematical modeling of aerosolized particle deposition 
suggests that three main factors are associated with particle 
penetration within the sinus: size of the ostium, pressure/
rate of flow of the aerosol, and particle size. Ostium size 
is the most significant factor. The authors concluded that 
ciliary action and respiration play a minor role in particle 
deposition, validating the use of a static cadaver model that 
has been used in subsequent studies of aerosolized delivery 
to the paranasal sinuses.15
Hyo et al15 theorized that the ideal particle size for aerosol 
delivery to the maxillary sinus would be 3–10 µm. However, 
an average of 3% of particles from 3 to 10 µm in diameter 
penetrates into the maxillary sinus. On the other hand, Saijo 
et al16 investigated the particle deposition of steady-state 
aerosol flow in the paranasal sinuses in a post-ESS cast 
model. They found that an insertion angle of 45° signifi-
cantly increased the particle deposition compared with a 30° 
  insertion. They also showed that higher flow rates, smaller 
particle size, and larger ostial diameter allow for better 
penetration into the maxillary sinus. Particles of 5.63 µm 
in diameter were deposited in the maxillary sinus in greater 
frequency than particles with a diameter of 16.37 µm.16
Negley et al17 studied the sinus deposition of technetium 
Tc99m administration by means of the RinoFlow™ nasal 
aerosol delivery device (Respironics, Inc, Cedar Grove, NJ) 
on five healthy subjects. The RinoFlow is a nebulizing device 
that delivers droplet particles in the 20–30 µm range in a 
controlled flow. Subjects were asked to voluntarily perform 
the Politzer maneuver (occluding the alternate nostril and 
swallowing) during nebulization. Three of the five subjects 
revealed incomplete and inconsistent deposition in the fron-
tal and maxillary sinuses. The sample size was too small to 
attain significance, but one should take into account that in 
subjects without any blockages of the ostiomeatal unit an 
insignificant amount of irrigation solution could be delivered 
into the paranasal sinuses.17
Olson et al18 also studied the distribution of nasal 
irrigation isotonic solutions in eight healthy, unoperated 
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volunteers by comparing three-dimensional computed 
tomography imaging of three irrigation techniques: positive-
pressure irrigation, negative-pressure irrigation, and passive-
diffusion nebulization. Positive-pressure irrigation was 
generated by a squeeze bottle such as the Sinus Rinse™ 
(NeilMed, Inc, Santa Rosa, CA), negative pressure was 
created through sniffing and nebulization was generated by 
the RinoFlow device. The RinoFlow nebulizer was found 
ineffective, consistent with the previous study: ethmoid 
penetration was achieved in only two cases. Interestingly, 
nasal irrigation was effective in the cases of spray bottle use 
and inhalation methods.18 Contrast solution reached ethmoid 
and maxillary sinuses that were more uniform irrigated 
in positive-pressure administration. The ethmoid sinuses 
were penetrated in seven subjects during negative-pressure 
irrigation and in six subjects during positive-pressure 
irrigation. Maxillary sinus irrigation was highest in the 
positive-pressure group versus the negative-pressure group 
(seven versus five) with bilateral involvement in five of 
eight subjects. However, the study demonstrated universally 
poor sphenoid and frontal sinus penetration. According to 
these results, the ability of an irrigation technique to deliver 
a solution to the paranasal sinuses should be related to 
sufficient pressure and high volume.18
Wormald et al19 compared the effectiveness of three meth-
ods of nasal irrigation: irrigation with a nasal spray bottle, 
nasal nebulizer, and nasal douching bottle with the subject in 
the kneeling position. The study was performed on nine CRS 
patients after ESS and three normal subjects. Sinus deposi-
tion was assessed by radioactivity of Tc99m sulfur colloid. 
There was no statistical difference in measured radioactivity 
between the surgical and healthy subjects. Nasal douche was 
the most effective in both postsurgical and normal subjects. 
However, one limitation of nasal douching is that it may be 
difficult for older patients or patients with arthritis to adopt 
the position required. Nasal cavity, maxillary sinus, and the 
frontal recess (not frontal sinus) were the accessible areas, 
but no technique was found to reliably penetrate the sphenoid 
or frontal sinus.19
Snidvongs et al20 conducted a clinical study to investigate 
how well nasal irrigation could reach the paranasal sinuses in 
CRS patients. Fourteen patients, with bilateral CRS, under-
went nasal irrigation with iodinated contrast solution. Nasal 
douching was carried out using an irrigation syringe in one 
side, and 10 mL of spray in the other. A computed tomog-
raphy scan was undertaken for each patient to determine the 
volume and distribution of staining. Only two patients had 
any staining, with a small amount present in a total of three 
maxillary sinuses. The authors demonstrated that the two 
techniques had a similar performance. Both of them delivered 
only a small amount of the solution, if any, into the sinuses. 
Blockages of the ostiomeatal complex may be a primary 
cause for the poor sinus solution penetration.20
Hwang et al7 investigated ten healthy subjects and five 
post-ESS subjects looking at sinus penetration of the SinuNeb 
device, the ViaNase device, and the nasal spray bottle. 
Using radiolabeled saline, poor sinus penetration was seen 
with all three systems. The vortex nebulizer had the greatest 
potential for sinus penetration with rates of 30% penetration 
for the frontal sinus, 10% for the maxillary sinus, and 30% 
for the sphenoid sinus. In contrast, the SinuNeb device and 
the spray bottle both showed 0% penetration for all sinuses. 
The sinus penetration for the postoperative group was col-
lectively poor.7
Valentine et al12 compared the sinus penetration of the 
PARI pulsed nebulizer to nasal irrigation with a squeeze 
bottle in a highly dissected cadaver model. Solutions were 
stained with methylene blue while staining intensity and 
colored area within the sinuses were assessed by three 
independent, blinded observers. The authors documented 
a significant increase in intensity of stain, percentage of 
stain, and circumference stained with the plastic nasal 
irrigation squeeze bottle versus the PARI device. Analysis 
of individual sinuses showed noteworthy increases in the 
indices of nasal douching relative to nebulization. In their 
study, 96% of all sinuses were stained by the squeeze bottle. 
The PARI device was noted to achieve ethmoid staining on a 
regular basis, whereas the other sinuses were inconsistently 
reached: frontal sinus, 43%; maxillary sinus, 46%, and 
sphenoid, 54%.12
In a recent study, Möller et al9,10 investigated sinus 
ventilation in healthy human volunteers using dynamic 
81mKr-gas imaging in combination with pulsating airflows. 
Ventilation is a basic requirement of aerosol delivery to the 
sinuses and subsequent deposition. 81mKr-gas was continu-
ously ventilated through the nasal airways with and without 
pulsation and sinus gas access was monitored using gamma 
camera imaging. Without pulsation, only the central nasal 
cavity appeared on the image. With pulsation, the maxillary 
and frontal sinuses appeared on the gamma camera image. 
Without pulsation, less than 5% of the total Kr-gas activity 
within the nasal cavity penetrated into the sinuses. This rate 
increased to about 48% with pulsation. In addition, pulsating 
airflow caused a sustained release of 81mKr-gas activity from 
the nasal cavity and the sinuses after switching off Kr-gas 
delivery. The authors suggest that this postponement can 
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cause an increased residence time of an aerosolized drug in 
the sinuses, further enhancing aerosol deposition.9,10
During the same study, the deposition efficiency of 
Tc99m-diethylene triamine pentaacetic acid aerosol delivered 
by pulsating airflow was assessed in each volunteer and 
compared to its deposition effectiveness using nasal 
pump sprays. A solution composed of Tc99m-diethylene 
triamine pentaacetic acid was delivered to each nostril 
for 20 seconds. The authors compared their results on 
distribution and clearance with those obtained after nasal 
pump spray delivery of a similar Tc99m-diethylene triamine 
pentaacetic acid solution. Nasal distribution was assessed by 
generating an image composed from lateral gamma camera 
images superimposed on a coronal magnetic resonance 
tomography scan of the volunteer. Nasal pump sprays gave 
anterior nasal airway deposition, and significant mucociliary 
clearance had already happened by the time the image 
was recorded.10 The pulsating aerosol delivery gave more 
posterior aerosol deposition, with access to the ostiomeatal 
complex. With pulsating aerosol delivery, the authors report 
that total deposition in the nasal cavity (including sinuses) 
of the five subjects was 71% ± 17% of the nebulized dose, 
and 6.5% ± 2.3% of the total nose activity (including 
sinuses) penetrated to the sinuses. In the same study it was 
demonstrated that by using the nasal pump spray, there was 
100% deposition of the administered activity, and less than 
1% of this dose penetrated into the sinuses.9
Aerosol delivered by nasal pump sprays has a high 
rate of clearance out of the nose: 50% was cleared after 
14.2 ± 3.4 minutes, and after 6 hours, less than 5% of activity 
was retained in the nose. In contrast, the pulsating aerosol 
delivery has retarded clearance kinetics: 50% of the dose 
was cleared after 1.2 ± 0.5 hours, and more than 20% of the 
administered dose was retained in the nose after 6 hours.9,10
The studies conducted by Möller et al9,10,13,14 have shown 
that drug delivery using pulsating aerosols was associated 
with slower clearance of the radiotracer from the nose com-
pared with nasal pump spray delivery, suggesting penetration 
into the nose to sites with retarded mucociliary clearance. 
The authors conclude that clearance kinetics in the range 
of hours using pulsating aerosol delivery, compared with 
10–20 minutes using nasal pump sprays, may provide longer 
residence times of a drug administered to the nose as a pulsat-
ing aerosol, and it may prevent rapid removal by mucocili-
ary clearance and by circulation.9,10,13,14 Therefore, pulsating 
aerosols may consent to formulations with sustained-release 
profiles and possibly once-daily application, even with 
shorter half-time values.9,14
Methods used to enhance drug 
distribution within the sinuses
Besides the delivery methods discussed previously, there 
are other methods used in clinical practice to enhance drug 
delivery to the sinuses: ESS and the position of the patient 
during nasal irrigation.6
Recent evidence supports the belief that ESS improves 
the delivery of topical medications to the sinus mucosa: 
Harvey et al8 studied the efficiency of nasal irrigation in ten 
cadavers and demonstrated that ESS significantly enhanced 
sinus delivery of medication, regardless of delivery device. 
ESS is essential to effectively allow topical distribution to 
the sinus mucosa.6,8,21 The frontal and sphenoid sinus are 
essentially inaccessible before surgery and according to 
Grobler et al22 an ostium size of greater than 4 mm is required 
to even begin drug penetration into the maxillary sinus. 
For those with mucosal edema and chronic inflammation, 
distribution is probably worse. For these reasons, Harvey 
and Schlosser6 stated that in medically managing CRS, 
the use of expensive and time-wasting topical therapies, 
such as increasing topical steroid options, are probably not 
supported prior to ESS.
There are conflicting reports on the most effective posi-
tion for drug delivery to the nasal cavity and paranasal 
sinuses. The majority of these studies involve assessment of 
dye distribution in the region of the middle turbinate with 
simple sprays and drops in nonoperated patients.23,24 Many 
commercial products recommend a head-down, over sink, 
with nose to ground position for irrigation. This orientation 
is practical and makes runoff easy to collect. One study 
demonstrated that the “Mygind” and “Ragan” (left lateral and 
supine positions) were superior to the “Mecca” and “Head 
Back” positions in delivery of drops to the middle meatus.25 
However, these results were found inconclusive by other 
investigators.26–30 The relevance of positioning with positive-
pressure irrigation is supposed to be less significant.27–32 
However, even with positive-pressure, high-volume irriga-
tion, the head-down or lateral position may lead to better 
frontal distribution.33
Clinical studies on the use  
of nebulized antibiotics in the 
management of CRS patients
It is common practice to prescribe prolonged courses of 
antibiotics during the medical management of CRS patients. 
Although widely accepted, this strategy is empirical and 
based in part upon culture reports available.2–4 In many 
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bacteriological culture studies, Staphylococcus aureus has 
been found to be a predominant species.3,4 Despite the con-
sistency of culture results positive for S. aureus, there is no 
consensus on whether or not its presence is of pathogenic 
importance. The secretion of various enzymes and toxins 
feeds the inflammatory reaction and preserves the recalci-
trance of the disease. Moreover S. aureus has been discussed 
in the literature because of its superantigen potentials and 
their apparent link to biofilm.3–5
Disadvantages of prolonged antibiotic administration 
include bacterial resistance, allergic reactions, nephrotoxic-
ity, ototoxicity, and gastrointestinal and hepatic disturbances. 
It has been suggested that topical application of antibiotics 
directly to the target site prevents these adverse effects of 
prolonged systemic administration, and avoids selection of 
resistant gut microflora. On the other hand, topical antibiotics 
have the theoretical advantage of acting directly on the site of 
infection and producing a higher concentration of antibiotic 
at the target site. Such increased concentrations of topical 
antibiotics have also been shown to be effective in killing 
bacteria in biofilm form.3
There is experimental evidence on the effectiveness 
of topical therapy in the management of CRS. Recently, 
Antunes et al34 reported on the dose-dependent effects of topi-
cal tobramycin in an animal model of Pseudomonas aerugi-
nosa sinusitis. They noted that as opposed to normal saline 
irrigations, topical tobramycin led to a significant improve-
ment in the degree of infection in this animal model.34
It is interesting that so few clinical studies have been 
conducted to explore the therapeutic option of nebulized 
antimicrobials in the treatment of CRS. In a prospective 
study, Kamijyo et al35 reported on 28 patients treated with 
fosfomycin nebulization three times a week for a period of 
4 weeks. Outcome measures included four subjective and 
five objective symptoms as well as cytokine concentrations. 
Improvement in terms of objective symptoms and endoscopic 
findings was rated as at least fair in about 60% of patients, 
except for the amount of secretion. Postnasal drip improved 
in 88% of the patients.35
Vaughan and Carvalho36 evaluated the effect of the nebu-
lization of several antimicrobials over a period of 3 months in 
42 patients with CRS. The authors compared the efficiency of 
six different culture-dependent nebulized antibiotics versus 
standard oral or intravenous antibiotic therapy. They reported 
significant improvements for posterior nasal discharge, 
facial pain, and emotional consequences. There was also an 
increase of the “disease-free interval period”: an average of 
17 weeks for nebulized therapy versus 6 weeks for standard 
therapy.36
In a retrospective evaluation, Scheinberg and Otsuji37 
reported on the effect of nebulized antibiotics for the treatment 
of acute exacerbations of CRS in 41 patients. Eighty-three 
percent of the patients improved on nasal obstruction, facial 
pain, rhinorrhea, and malaise after administration of nebu-
lized antibiotics. The researchers concluded that nebulized 
antibiotics should be considered for all patients with CRS 
who have undergone ESS and who have failed to respond to 
oral antibiotics or who do not tolerate them.37
Kobayashi and Baba38 used an ultrasound-type inhaler 
and studied therapy with aminoglycoside, fosfomycin, and 
cefmenoxime three times per week. Their findings suggested 
that in patients without previous sinus surgery, the main 
effect of the nebulized medications was in the nose, with 
only an indirect effect on the maxillary sinuses: no experi-
mental evidence was found of antibiotic penetration into the 
maxillary sinus.38
In a randomized, double-blind trial Desrosiers and 
Salas-Prato39 reported that both tobramycin-saline solution 
and aerosolized saline solution led to equal improvements 
in quality of life, symptoms, and endoscopic aspects of the 
nasal mucosa. The addition of tobramycin appears of mini-
mal benefit.39
Videler et al40 conducted a randomized, placebo-
  controlled, double-blind, cross-over pilot study on 14 patients 
with recalcitrant CRS. Nasal irrigation with bacitracin/
colimycin or placebo using the RhinoFlow nebulizer twice 
daily was administered in combination with oral levofloxacin. 
Outcome measures included symptomatic relief, quality of 
life scores, and endoscopic findings. The study demonstrated 
that in patients with therapy-resistant CRS, many symptoms 
have a tendency to decrease compared with the pretreat-
ment period after using the nebulizer in combination with 
levofloxacin. None of the analyses comparing the bacitracin/
colimycin group with placebo, however, identified significant 
differences. Therefore this study has not confirmed any addi-
tional effect of the locally administered antibiotics.40
Emerging evidence from a recent review suggests that 
topical antibiotics may be useful as a treatment modality in 
CRS and its exacerbations.41 Current corroborating evidence, 
at a relatively low level of evidence, points to the efficacy 
of nasal irrigation or nebulization rather than delivery by 
nasal spray. For the antibacterial studies, the highest level of 
evidence currently exists for studies that have used postsur-
gical patients and culture-directed therapy. Both stable and 
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acute exacerbations of CRS appear to benefit from topical 
antibiotics.41
In the same review, it is suggested that topical antibiotics 
should not be first-line management but may be attempted 
in patients refractory to the traditional topical steroids and 
oral antibiotics.41
Larger and better-designed, randomized, double-blind, 
placebo-controlled trials are required to more fully evaluate 
this modality of treatment. In particular, the control group 
for these future studies should be an equivalent sinus placebo 
rather than alternative methods of therapy. Additional stud-
ies could also directly compare different delivery methods, 
surgical and nonsurgical patients, and culture-directed versus 
empiric treatment.
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